These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34192990)

  • 1. Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting.
    Wu CC; Hsu YT; Chang CL
    Int J Hyperthermia; 2021; 38(1):1013-1022. PubMed ID: 34192990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
    Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?
    de Bree E; Katsougkri D; Polioudaki H; Tsangaridou E; Michelakis D; Zoras O; Theodoropoulos P
    Anticancer Res; 2020 Dec; 40(12):6769-6780. PubMed ID: 33288570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.
    Bespalov VG; Kireeva GS; Belyaeva OA; Kalinin OE; Senchik KY; Stukov AN; Gafton GI; Guseynov KD; Belyaev AM
    J Surg Oncol; 2016 Mar; 113(4):438-42. PubMed ID: 26710749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
    Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Schwameis R; Chiva L; Harter P
    Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
    [No Abstract]   [Full Text] [Related]  

  • 7. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer.
    Brennan DJ; Driel WJV; Zivanovic O
    Int J Gynecol Cancer; 2023 May; 33(5):851-852. PubMed ID: 36898700
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.
    Polom K; Roviello G; Generali D; Marano L; Petrioli R; Marsili S; Caputo E; Marrelli D; Roviello F
    Int J Hyperthermia; 2016 May; 32(3):298-310. PubMed ID: 26984715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
    Rettenmaier MA; Micha JP; Bohart R; Goldstein BH
    Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():101-105. PubMed ID: 31778904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.
    de Bree E; Helm CW
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):895-911. PubMed ID: 22845405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
    Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
    Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I do Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in ovarian cancer: a 10 steps video ?
    Duchon M; Sousa C; Dion L; Lavoué V
    J Gynecol Obstet Hum Reprod; 2023 May; 52(5):102563. PubMed ID: 36858197
    [No Abstract]   [Full Text] [Related]  

  • 15. Intraperitoneal hyperthermic chemotherapy in ovarian cancer.
    Gori J; Castaño R; Toziano M; Häbich D; Staringer J; De Quirós DG; Felci N
    Int J Gynecol Cancer; 2005; 15(2):233-9. PubMed ID: 15823105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
    Koole SN; van Driel WJ; Sonke GS
    Cancer; 2019 Dec; 125 Suppl 24():4587-4593. PubMed ID: 31967678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI).
    Steffen T; Häller L; Bijelic L; Glatzer M; Glehen O; Goéré D; de Hingh I; Li Y; Moran BJ; Morris DL; Piso P; Quadros CA; Rau B; Sugarbaker P; Yonemura Y; Putora PM
    Oncology; 2021; 99(1):41-48. PubMed ID: 32920557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer.
    Bespalov VG; Alvovsky IK; Tochilnikov GV; Stukov AN; Vyshinskaya EA; Semenov AL; Vasilyeva IN; Belyaeva OA; Kireeva GS; Senchik KY; Zhilinskaya NT; Von JD; Krasilnikova LA; Alexandrov VA; Khromov-Borisov NN; Baranenko DA; Belyaev AM
    Int J Hyperthermia; 2018 Aug; 34(5):545-550. PubMed ID: 28893108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Moukarzel LA; Ferrando L; Dopeso H; Stylianou A; Basili T; Pareja F; Da Cruz Paula A; Zoppoli G; Abu-Rustum NR; Reis-Filho JS; Long Roche K; Tew WP; Chi DS; Sonoda Y; Zamarin D; Aghajanian C; O'Cearbhaill RE; Zivanovic O; Weigelt B
    Gynecol Oncol; 2022 May; 165(2):239-247. PubMed ID: 35292180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.
    Hotouras A; Desai D; Bhan C; Murphy J; Lampe B; Sugarbaker PH
    Int J Gynecol Cancer; 2016 May; 26(4):661-70. PubMed ID: 26844612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.